Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin

被引:9
|
作者
Yang, Emily Y. [1 ]
Howard, Grant R. [2 ]
Brock, Amy [2 ,3 ,4 ]
Yankeelov, Thomas E. [1 ,2 ,3 ,5 ,6 ,7 ]
Lorenzo, Guillermo [1 ,8 ]
机构
[1] Univ Texas Austin, Oden Inst Computat Engn & Sci, Austin, TX 78712 USA
[2] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA
[3] Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78712 USA
[4] Univ Texas Austin, Interdisciplinary Life Sci Program, Austin, TX 78712 USA
[5] Univ Texas Austin, Dept Diagnost Med, Austin, TX 78712 USA
[6] Univ Texas Austin, Dept Oncol, Austin, TX 78712 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA
[8] Univ Pavia, Dept Civil Engn & Architecture, Pavia, Italy
基金
美国国家卫生研究院;
关键词
mathematical oncology; mathematical modeling; population dynamics; chemotherapy; drug resistance; breast cancer; time-resolved microscopy; DRUG-RESISTANCE; TUMOR HETEROGENEITY; DOSE-DENSE; NEOADJUVANT THERAPY; RANDOMIZED-TRIAL; LOGISTIC MODEL; CHEMOTHERAPY; MECHANISMS; SCHEDULE; SURVIVAL;
D O I
10.3389/fmolb.2022.972146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of chemoresistance remains a significant cause of treatment failure in breast cancer. We posit that a mathematical understanding of chemoresistance could assist in developing successful treatment strategies. Towards that end, we have developed a model that describes the cytotoxic effects of the standard chemotherapeutic drug doxorubicin on the MCF-7 breast cancer cell line. We assume that treatment with doxorubicin induces a compartmentalization of the breast cancer cell population into surviving cells, which continue proliferating after treatment, and irreversibly damaged cells, which gradually transition from proliferating to treatment-induced death. The model is fit to experimental data including variations in drug concentration, inter-treatment interval, and number of doses. Our model recapitulates tumor cell dynamics in all these scenarios (as quantified by the concordance correlation coefficient, CCC > 0.95). In particular, superior tumor control is observed with higher doxorubicin concentrations, shorter inter-treatment intervals, and a higher number of doses (p < 0.05). Longer inter-treatment intervals require adapting the model parameterization after each doxorubicin dose, suggesting the promotion of chemoresistance. Additionally, we propose promising empirical formulas to describe the variation of model parameters as functions of doxorubicin concentration (CCC > 0.78). Thus, we conclude that our mathematical model could deepen our understanding of the cytotoxic effects of doxorubicin and could be used to explore practical drug regimens achieving optimal tumor control.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes
    Song, Xingli
    Ren, Yi
    Zhang, Jing
    Wang, Gang
    Han, Xuedong
    Zheng, Wei
    Zhen, Linlin
    ONCOLOGY REPORTS, 2015, 34 (04) : 1953 - 1960
  • [42] Cell growth analysis and nucleotide excision repair modulation in breast cancer cells submitted to a protocol using doxorubicin and paclitaxel
    Busatto, Franciele Faccio
    Viero, Victoria Pereira
    Schaefer, Bruna Thais
    Saffi, Jenifer
    LIFE SCIENCES, 2021, 268
  • [43] Simultaneous proteasome and autophagy inhibition synergistically enhances cytotoxicity of doxorubicin in breast cancer cells
    Loh, Jian Sheng
    Rahim, Nusaibah Abdul
    Tor, Yin Sim
    Foo, Jhi Biau
    CELL BIOCHEMISTRY AND FUNCTION, 2022, 40 (04) : 403 - 416
  • [44] Effects of doxorubicin and gemcitabine on the induction of apoptosis in breast cancer cells
    Zheng, Rui-Rui
    Hu, Wei
    Sui, Cheng-Guang
    Ma, Nan
    Jiang, You-Hong
    ONCOLOGY REPORTS, 2014, 32 (06) : 2719 - 2725
  • [45] Doxorubicin Influences the Expression of Glucosylceramide Synthase in Invasive Ductal Breast Cancer
    Zhang, Xiaofang
    Wu, Xiaojuan
    Su, Peng
    Gao, Yongsheng
    Meng, Bin
    Sun, Yanlin
    Li, Li
    Zhou, Zhiqiang
    Zhou, Gengyin
    PLOS ONE, 2012, 7 (11):
  • [46] Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells
    Shi, Yonghua
    Bieerkehazhi, Shayahati
    Ma, Hong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (05): : 2347 - 2355
  • [47] Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population
    Weinberg, Marc S.
    Shachar, Shlomit S.
    Muss, Hyman B.
    Deal, Allison M.
    Popuri, Karteek
    Yu, Hyeon
    Nyrop, Kirsten A.
    Alston, Shani M.
    Williams, Grant R.
    BREAST JOURNAL, 2018, 24 (03) : 278 - 284
  • [48] Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells
    Ambrosio, Maria Rosaria
    D'Esposito, Vittoria
    Costa, Valerio
    Liguoro, Domenico
    Collina, Francesca
    Cantile, Monica
    Prevete, Nella
    Passaro, Carmela
    Mosca, Giusy
    De laurentiis, Michelino
    Di Bonito, Maurizio
    Botti, Gerardo
    Franco, Renato
    Beguinot, Francesco
    Ciccodicola, Alfredo
    Formisano, Pietro
    ONCOTARGET, 2017, 8 (65) : 109000 - 109017
  • [49] The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells
    Li, Shi-zheng
    Li, Kun
    Zhang, Jun-hua
    Dong, Zhe
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (02) : 352 - 355
  • [50] Distinct characterization of two vinorelbine-resistant breast cancer cell lines developed by different strategies
    Xu, Mingjie
    Jiang, Donghai
    Shen, Jiaying
    Zheng, Huilin
    Fan, Weimin
    ONCOLOGY REPORTS, 2016, 35 (04) : 2355 - 2363